Group 1 - The core viewpoint of the article is that Yuexiu Capital (000987) clarified its investment in Guangdong Xinxin Semiconductor, stating that it is a subsidiary of the company and that this investment will not significantly impact the company's operating performance [1] Group 2 - Guangdong Xinxin Semiconductor is one of the investment enterprises under Yuexiu Capital's subsidiary, Yuexiu Industrial Fund Management [1] - The company responded to investor inquiries on its interactive platform regarding the implications of this investment [1] - The investment in Guangdong Xinxin Semiconductor is not expected to have a major effect on the overall financial results of Yuexiu Capital [1]

越秀资本1月6日在互动平台表示，粤芯半导体是公司控股子公司越秀产业基金管理基金的投资企业之 一，该投资不会对公司经营业绩产生重大影响。 ...

Core Viewpoint - The article discusses the recent IPO counseling completion of two leading companies in the commercial aerospace sector, Zhongke Aerospace and Weina Starry Sky, highlighting their significance in the "bottleneck" technology space and the investment strategies of Yuexiu Capital [1] Group 1: Company Information - Zhongke Aerospace completed its IPO counseling registration on August 12, while Weina Starry Sky completed theirs on September 15 [1] - Yuexiu Industrial Fund holds a 2.49% stake in Zhongke Aerospace and a 0.596% stake in Weina Starry Sky, indicating a strategic investment in these companies [1] Group 2: Investment Strategy - The companies are part of Yuexiu Capital's strategy to create a complete investment loop encompassing "rockets-satellites-applications" [1] - Yuexiu Capital stated that the investments in Zhongke Aerospace and Weina Starry Sky will not significantly impact the company's operating performance [1]

Core Viewpoint - The diversified financial sector experienced a significant increase of 2.12% on January 6, with Yuexiu Capital leading the gains, while the Shanghai Composite Index rose by 1.5% and the Shenzhen Component Index increased by 1.4% [1] Group 1: Market Performance - The closing price of Yuexiu Capital was 66.8, reflecting a rise of 4.66% with a trading volume of 1.5541 million shares and a transaction value of 1.372 billion [1] - Lakala's closing price was 27.53, up by 4.60%, with a trading volume of 1.1559 million shares and a transaction value of 3.17 billion [1] - Nanhua Futures closed at 20.39, increasing by 3.66%, with a trading volume of 145,600 shares and a transaction value of 294 million [1] Group 2: Capital Flow - The diversified financial sector saw a net inflow of 97.8627 million from main funds, while retail investors experienced a net outflow of 70.4892 million [1] - Yuexiu Capital had a main fund net inflow of 97.1413 million, with retail investors showing a net outflow of 80.4966 million [2] - Hainan Huatie recorded a main fund net inflow of 77.1252 million, while retail investors faced a net outflow of 79.0077 million [2]

1月6日，越秀资本涨5.94%，截至发稿，报9.10元/股，成交10.88亿元，换手率2.48%，总市值456.56亿 元。 截至发稿，罗文杰累计任职时间12年263天，现任基金资产总规模1702.51亿元，任职期间最佳基金回报 156.65%， 任职期间最差基金回报-47.6%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，南方基金旗下1只基金位居越秀资本十大流通股东。南方中证500ETF（510500）三季度减持 52.71万股，持有股数2198万股，占流通股的比例为0.44%。根据测算，今日浮盈赚取约1120.98万元。 南方中证500ETF（510500）成立日期2013年2月6日，最新规模1400.98亿。今年以来收益2.5%，同类排 名1861/5490；近一年收益43.41%，同类排名1442/4193；成立以来收益157.95%。 南方中证500ETF（510500）基金经理为罗文杰。 资料显示，广州越秀资本控股集团股份有 ...

广州越秀资本控股集团股份有限公司 总经理工作细则 （2026 年 1 月） 股票代码：000987 第一章 总 则 第一条 为促进广州越秀资本控股集团股份有限公司（以下简称"公司"或"本 公司"）的规范运作和健康发展，完善法人治理结构体系，根据《中华人民共和国公 司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》（以下简称"上市 规则"）《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、 公司《章程》等有关规定，特制定本细则。 第二条 本细则所称的公司高级管理人员是指公司总经理、副总经理、财务负责 人、董事会秘书及经公司董事会确定的其他管理人员。 第二章 高级管理人员职权 第三条 总经理对董事会负责，行使下列职权： （一）主持公司的经营管理工作，组织实施董事会决议，并向董事会报告工作； 第四条 副总经理及其他高级管理人员的主要职权： （一）协助总经理工作，并对总经理负责； （二）按照工作分工，分管相应的部门或工作，并承担相应的责任； （三）在分管工作范围内，对部门（或单位）负责人的任免、机构设置（变更）、 建章立制等事项提出建议； （四）在分管工作范围内，根据工作需要决定召开 ...

证券代码：000987 证券简称：越秀资本 公告编号：2026-002 根据公司《2024 年度核心人员持股计划管理办法》相关规 定，本核心人员持股计划锁定期届满后、存续期届满前，将根据 归属条件确定可归属股票额度，经持有人确认后，将本计划持有 的全部股票及资金权益（如有）归属至持有人；对于无未来归属 对象的股票及现金资产，应于股票锁定期满后由管理委员会在二 级市场减持变现后将资金（含孳息）归还公司，现金资产（含孳 息）直接归还公司。 2024 年度核心人员持股计划锁定期届满后、存续期届满前， 因部分原持有人离职等原因而产生的无未来归属对象的股票共 计 223,970 股，占公司总股本的 0.0045%。该部分股票已由 2024 年度持股计划管理委员会通过二级市场完成出售，所得资金及该 部分股票产生的孳息共 1,700,143.86 元已归还公司。本期股票购 买及无未来归属对象股票的出售均严格遵守市场交易规则及持 股计划管理办法，未出现信息敏感期操作和内幕交易等违法违规 情况。 截至本公告发布日，公司已通过非交易过户的形式将 2024 年度核心人员持股计划股票归属至 54 名持有人个人账户。其中， 党委书记、 ...

证券代码：000987 证券简称：越秀资本 公告编号：2026-001 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 广州越秀资本控股集团股份有限公司（以下简称"公司"）第 十届董事会第三十一次会议通知于 2025 年 12 月 27 日以电子邮 件方式发出，会议以通讯方式召开并于 2026 年 1 月 5 日完成通 讯表决。本次会议应出席董事 12 人，实际出席董事 12 人。本次 会议的召集和召开程序符合《公司法》和公司《章程》等有关规 定。 与会董事经审议表决，形成以下决议： 一、以 12 票同意、0 票反对、0 票弃权，审议通过《关于 修订<总经理工作细则>的议案》 根据《公司法》《证券法》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公 司规范运作》等法律法规及监管规则，结合当前经营管理实际情 况，同意公司对《总经理工作细则》予以修订。 修订后的《总经理工作细则》全文详见公司同日发布在巨潮 资讯网（www.cninfo.com.cn）的相关公告。 二、以 12 票同意、0 票反对、0 票弃权，审议通过《关于 ...

Core Viewpoint - The diversified financial sector experienced a rise of 0.58% on January 5, with Zhejiang Dongfang leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1]. - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1]. Group 2: Individual Stock Performance - Zhejiang Dongfang (600120) closed at 6.59, with a gain of 6.81% and a trading volume of 2.1745 million shares, amounting to a transaction value of 1.424 billion [1]. - Yuexiu Capital (000987) closed at 8.59, up by 5.53%, with a trading volume of 1.4263 million shares, totaling 1.225 billion [1]. - Sichuan Shuangma (000935) closed at 25.44, increasing by 2.42%, with a trading volume of 80,800 shares, resulting in a transaction value of 205 million [1]. - Guowang Yingda (600517) closed at 6.15, up by 2.33%, with a trading volume of 358,600 shares, totaling 219 million [1]. - Zhongliang Capital (002423) closed at 11.90, increasing by 1.71%, with a trading volume of 185,500 shares, resulting in a transaction value of 219 million [1]. Group 3: Fund Flow Analysis - The diversified financial sector saw a net outflow of 433 million from main funds, while retail investors contributed a net inflow of 368 million [2]. - The main funds' net inflow for Zhejiang Dongfang was 263.14 million, accounting for 18.48% of its trading volume [3]. - Retail investors showed a net inflow of 368 million into the diversified financial sector, indicating strong interest from smaller investors [2].

Core Viewpoint - The article discusses the growth and development of Ruipai Pet, a national chain of pet medical institutions in China, founded by Li Shoujun, who transitioned from a state-owned enterprise to entrepreneurship. The company is preparing for a potential listing on the Hong Kong stock market, which could enhance its presence in the international capital market [2][3]. Group 1: Company Overview - Ruipai Pet was established in December 2012 with a registered capital of 100 million yuan, primarily owned by Zhongrui Huapu and individual shareholders [3]. - The company has undergone multiple financing rounds, raising a total of 2.147 billion yuan from investors including Mars China and Goldman Sachs [3][4]. - As of the first half of 2025, Ruipai Pet operates 548 pet hospitals, making it the second-largest pet medical service provider in China [19]. Group 2: Financial Performance - Ruipai Pet's revenue has shown consistent growth, with figures of 1.455 billion yuan in 2022, 1.585 billion yuan in 2023, and projected 1.758 billion yuan in 2024, alongside a revenue of 943.13 million yuan in the first half of 2025, reflecting an 8.52% year-on-year increase [19][20]. - The core business of diagnostic services has also seen growth, with revenues of 1.296 billion yuan in 2022 and projected 1.593 billion yuan in 2024 [19]. - The gross profit margin for Ruipai Pet has fluctuated, with a margin of 22.4% in 2022, 21.0% in 2023, and increasing to 24.8% in the first half of 2025 [27][28]. Group 3: Ownership and Control - Li Shoujun, the actual controller of Ruipai Pet, holds a 26.91% stake in the company through Zhongrui Huapu and Ruipu Biology [8]. - The company has seen various shareholders transfer their stakes, with significant transactions occurring in 2020 and 2022, indicating active management of equity [5][6]. Group 4: Operational Insights - Ruipai Pet's hospitals are primarily acquired, with 428 out of 548 hospitals being obtained through acquisitions [21]. - The company has a diverse range of services, including pet product sales and grooming services, although these contribute a smaller portion of total revenue compared to diagnostic services [19][23]. - The average revenue contribution per city center hospital is significantly higher than that of community hospitals, indicating a strategic focus on higher-margin facilities [21]. Group 5: Future Prospects - Ruipai Pet is preparing for a potential IPO, which could provide additional capital for expansion and enhance its market position [2][3]. - The company has maintained positive operating cash flow, with net inflows of 2.92 billion yuan in 2022 and 2.63 billion yuan in the first half of 2025 [29].